Jump to content

Lotte Bjerre Knudsen: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎Contributions: Completed the Molteni STAT citation, and removed two inline tags.
Made date presentations uniform via {{use dmy dates}] markup, and completed the Knudsen and Drucker journal citations.
Line 1: Line 1:
{{Short description|Danish scientist}}
{{Short description|Danish scientist}}
{{use dmy dates}}
{{multiple issues|
{{multiple issues|
{{primary sources|date = May 2024}}
{{primary sources|date = May 2024}}
Line 5: Line 6:
{{Full citations needed|date = May 2024}}
{{Full citations needed|date = May 2024}}
}}
}}
'''Lotte Bjerre Knudsen''' (born March 10, 1964) is a Danish [[scientist]] and [[Academic staff|university professor]]. She has led the development of [[liraglutide]] and [[semaglutide]], two notable drugs against [[diabetes]] and [[obesity]].{{fact|date = May 2024}}<!--For obvious reasons, a self-authored publication—"I discovered X first"—cannot establish primacy of discovery in STEM or other scholarly areas. Required is a consensus of independent, third-party, secondary sources.--><ref name="Knudsen">L. B. Knudsen, J. Lau: ''The Discovery and Development of Liraglutide and Semaglutide.'' In: ''Frontiers in Endocrinology.'' Band 10, 2019, S.&nbsp;155, {{doi|10.3389/fendo.2019.00155}}, PMID 31031702, {{PMC|6474072}}.
'''Lotte Bjerre Knudsen''' (born March 10, 1964) is a Danish [[scientist]] and [[Academic staff|university professor]]. She has led the development of [[liraglutide]] and [[semaglutide]], two notable drugs against [[diabetes]] and [[obesity]].{{third party inline|date=May 2024}}<!--For obvious reasons, a self-authored publication—"I discovered X first"—cannot establish primacy of discovery in STEM or other scholarly areas. Required is a consensus of independent, third-party, secondary sources.--><ref name="Knudsen">{{cite journal | author = Knudsen, L. B. & Lau, J. | date = 11 April 2019 | title = The Discovery and Development of Liraglutide and Semaglutide | journal = Front. Endocrinol. [Mol. Struct. Endocrinol. §] | volume = 10 | issue = | pages = | doi = 10.3389/fendo.2019.00155 | url = https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00155 | access-date=2024-05-13 | pmid = 31031702 | pmc = 6474072 | issn = 1664-2392}}{{third party inline|date=May 2024}}</ref>
</ref>


== Early life and education==
== Early life and education==
Line 19: Line 19:
While still a student, Knudsen worked at Novo Nordisk, initially working on laundry detergent enzymes. Alongside fellow student Shamkant Patkar, she discovered an enzyme capable of removing microscopic strands of cotton that pill up on clothing from repeated wear.<ref name="statnews">{{cite web| author = Molteni, Megan | date = 17 October 2023 | title=How One Scientist's Determination Made Novo Nordisk an Obesity-Drug Powerhouse|work = [[Stat (website)|STAT]]|url=https://www.statnews.com/2023/10/17/lotte-knudsen-novo-nordisk-obesity-drug-liraglutide-ozempic-wegovy/|access-date=2024-04-21|url-access=subscription}}</ref>
While still a student, Knudsen worked at Novo Nordisk, initially working on laundry detergent enzymes. Alongside fellow student Shamkant Patkar, she discovered an enzyme capable of removing microscopic strands of cotton that pill up on clothing from repeated wear.<ref name="statnews">{{cite web| author = Molteni, Megan | date = 17 October 2023 | title=How One Scientist's Determination Made Novo Nordisk an Obesity-Drug Powerhouse|work = [[Stat (website)|STAT]]|url=https://www.statnews.com/2023/10/17/lotte-knudsen-novo-nordisk-obesity-drug-liraglutide-ozempic-wegovy/|access-date=2024-04-21|url-access=subscription}}</ref>


After this project, Knudsen joined full-time as part of a research group at Novo Nordisk that aimed to identify new treatments for [[diabetes]], by developing [[small molecule]] drugs targeting specific metabolic pathways.{{fact|date=May 2024}} One project revolved around [[glucagon-like peptide-1]],{{fact|date=May 2024}} a hormone that stimulates the production of [[insulin]] but has a short [[half-life]] of minutes in the body.<ref name="Knudsen"/>{{third party inline|date=May 2024}} [[Glucagon-like peptide-1]] had been previously identified by researchers such as Jens Juul Holst in Denmark, who joined Novo Nordisk as a consultant,<ref name="statnews"/>{{full|date = May 2024}} and [[Joel Habener]], [[Daniel J. Drucker]], and [[Svetlana Mojsov]] at [[Massachusetts General Hospital]].<ref>{{cite web|url=https://www.jci.org/articles/view/97233|title=Discovery, characterization, and clinical development of the glucagon-like peptides|access-date=2024-04-21}}{{full|date = May 2024}}</ref>{{full|date = May 2024}}<ref>{{cite web|url=https://www.nature.com/articles/d41586-023-03927-1|title=Weight-loss-drug pioneer: this biochemist finally gained recognition for her work|access-date=2024-04-21}}{{full|date = May 2024}}</ref>{{full|date = May 2024}}
After this project, Knudsen joined full-time as part of a research group at Novo Nordisk that aimed to identify new treatments for [[diabetes]], by developing [[small molecule]] drugs targeting specific metabolic pathways.{{fact|date=May 2024}} One project revolved around [[glucagon-like peptide-1]],{{fact|date=May 2024}} a hormone that stimulates the production of [[insulin]] but has a short [[half-life]] of minutes in the body.<ref name="Knudsen"/>{{third party inline|date=May 2024}} [[Glucagon-like peptide-1]] had been previously identified by researchers such as Jens Juul Holst in Denmark, who joined Novo Nordisk as a consultant,<ref name="statnews"/>{{full|date = May 2024}} and [[Joel Habener]], [[Daniel J. Drucker]], and [[Svetlana Mojsov]] at [[Massachusetts General Hospital]].<ref>{{cite journal | author = Drucker, Daniel J.; Habener, Joel F. & Holst, Jens Juul | date = 1 December 2017 | title = Discovery, Characterization, and Clinical Development of the Glucagon-like Peptides | journal = J. Clin. Invest. | volume = 127 | issue = 12 | pages = 4217-4227 | doi = 10.1172/JCI97233 | url = https://www.jci.org/articles/view/97233 | access-date=2024-04-21 }}</ref><ref>{{cite web|url=https://www.nature.com/articles/d41586-023-03927-1|title=Weight-loss-drug pioneer: this biochemist finally gained recognition for her work|access-date=2024-04-21}}{{full|date = May 2024}}</ref>{{full|date = May 2024}}


Knudsen's team screened numerous chemical compounds to identify whether they could bind to the [[glucagon-like peptide-1 receptor]] sufficiently to stimulate insulin secretion.<ref name="statnews"/>{{full|date = May 2024}} Eventually, they developed a new compound called [[liraglutide]], which is an agonist for the [[glucagon-like peptide-1 receptor]].<ref name="statnews"/>{{full|date = May 2024}} It is a [[chemical analogue]] of [[glucagon-like peptide-1]], with a fatty acid and spacer attached. These modifications increased its ability to dissolve in water and bind to [[albumin]], which increase its [[bioavailability]]—its lifetime in the bloodstream, and so the duration of its action in the body.{{third party inline|date=May 2024}}<ref name="Knudsen"/> Liraglutide was approved as a treatment for diabetes under the brand name Victoza in the United States in 2010.<ref>{{cite journal|url=https://pubmed.ncbi.nlm.nih.gov/26106933/|title=Liraglutide for Type 2 diabetes and obesity: a 2015 update|date=2015 |pmid=26106933 |last1=Iepsen |first1=E. W. |last2=Torekov |first2=S. S. |last3=Holst |first3=J. J. |journal=Expert Review of Cardiovascular Therapy |volume=13 |issue=7 |pages=753–767 |doi=10.1586/14779072.2015.1054810 }}</ref>
Knudsen's team screened numerous chemical compounds to identify whether they could bind to the [[glucagon-like peptide-1 receptor]] sufficiently to stimulate insulin secretion.<ref name="statnews"/>{{full|date = May 2024}} Eventually, they developed a new compound called [[liraglutide]], which is an agonist for the [[glucagon-like peptide-1 receptor]].<ref name="statnews"/>{{full|date = May 2024}} It is a [[chemical analogue]] of [[glucagon-like peptide-1]], with a fatty acid and spacer attached. These modifications increased its ability to dissolve in water and bind to [[albumin]], which increase its [[bioavailability]]—its lifetime in the bloodstream, and so the duration of its action in the body.{{third party inline|date=May 2024}}<ref name="Knudsen"/> Liraglutide was approved as a treatment for diabetes under the brand name Victoza in the United States in 2010.<ref>{{cite journal|url=https://pubmed.ncbi.nlm.nih.gov/26106933/|title=Liraglutide for Type 2 diabetes and obesity: a 2015 update|date=2015 |pmid=26106933 |last1=Iepsen |first1=E. W. |last2=Torekov |first2=S. S. |last3=Holst |first3=J. J. |journal=Expert Review of Cardiovascular Therapy |volume=13 |issue=7 |pages=753–767 |doi=10.1586/14779072.2015.1054810 }}</ref>

Revision as of 17:48, 13 May 2024

Lotte Bjerre Knudsen (born March 10, 1964) is a Danish scientist and university professor. She has led the development of liraglutide and semaglutide, two notable drugs against diabetes and obesity.[third-party source needed][1]

Early life and education

Knudsen originally studied chemical engineering at the Technical University of Denmark,[citation needed] and obtained a doctorate in scientific medicine (DMSc) from the University of Copenhagen in 2014.[2]

Career

Knudsen began work as a scientist at the pharmaceutical company Novo Nordisk in Denmark in 1989.[2] She served as an adjunct faculty member at Aarhus University from 2015-2020, as a professor in translational medicine.[2]

Since January 2022, Knudsen has been employed as the Chief Scientific Advisor [for] Research at Novo Nordisk.[third-party source needed][3]

Contributions

While still a student, Knudsen worked at Novo Nordisk, initially working on laundry detergent enzymes. Alongside fellow student Shamkant Patkar, she discovered an enzyme capable of removing microscopic strands of cotton that pill up on clothing from repeated wear.[4]

After this project, Knudsen joined full-time as part of a research group at Novo Nordisk that aimed to identify new treatments for diabetes, by developing small molecule drugs targeting specific metabolic pathways.[citation needed] One project revolved around glucagon-like peptide-1,[citation needed] a hormone that stimulates the production of insulin but has a short half-life of minutes in the body.[1][third-party source needed] Glucagon-like peptide-1 had been previously identified by researchers such as Jens Juul Holst in Denmark, who joined Novo Nordisk as a consultant,[4][full citation needed] and Joel Habener, Daniel J. Drucker, and Svetlana Mojsov at Massachusetts General Hospital.[5][6][full citation needed]

Knudsen's team screened numerous chemical compounds to identify whether they could bind to the glucagon-like peptide-1 receptor sufficiently to stimulate insulin secretion.[4][full citation needed] Eventually, they developed a new compound called liraglutide, which is an agonist for the glucagon-like peptide-1 receptor.[4][full citation needed] It is a chemical analogue of glucagon-like peptide-1, with a fatty acid and spacer attached. These modifications increased its ability to dissolve in water and bind to albumin, which increase its bioavailability—its lifetime in the bloodstream, and so the duration of its action in the body.[third-party source needed][1] Liraglutide was approved as a treatment for diabetes under the brand name Victoza in the United States in 2010.[7]

Knudsen's team then worked on what became semaglutide, which had greater stability and affinity to albumin, lengthening its duration of action further to a once-weekly drug.[third-party source needed][8][non-primary source needed] Semaglutide was approved in the United States under the brand name Ozempic as a treatment for type 2 diabetes in 2017[9][full citation needed] and under the brand name Wegovy for chronic weight management in 2021.[10][full citation needed]

Honors

Knudsen received the 2023 Paul Langerhans Medal by the German Diabetes Society for her work developing the GLP-1 receptor agonist (GLP-1 RA) Liraglutide,[11][12] and in October 2023, she received the STAT Biomedical Innovation award.[13]

External links

References

  1. ^ a b c Knudsen, L. B. & Lau, J. (11 April 2019). "The Discovery and Development of Liraglutide and Semaglutide". Front. Endocrinol. [Mol. Struct. Endocrinol. §]. 10. doi:10.3389/fendo.2019.00155. ISSN 1664-2392. PMC 6474072. PMID 31031702. Retrieved 13 May 2024.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)[third-party source needed]
  2. ^ a b c Müller, Martin U.; Preker, Alexander (4 January 2024). "Interview with Weight Loss Drugs Inventor Lotte Bjerre Knudsen: "I'm Experimenting with Periodic Fasting"". Der Spiegel. Retrieved 6 January 2024.
  3. ^ "Experience | Lotte Bjerre Knudsen | LinkedIn". LinkedIn. Retrieved 21 April 2024.[third-party source needed]
  4. ^ a b c d Molteni, Megan (17 October 2023). "How One Scientist's Determination Made Novo Nordisk an Obesity-Drug Powerhouse". STAT. Retrieved 21 April 2024.
  5. ^ Drucker, Daniel J.; Habener, Joel F. & Holst, Jens Juul (1 December 2017). "Discovery, Characterization, and Clinical Development of the Glucagon-like Peptides". J. Clin. Invest. 127 (12): 4217–4227. doi:10.1172/JCI97233. Retrieved 21 April 2024.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ "Weight-loss-drug pioneer: this biochemist finally gained recognition for her work". Retrieved 21 April 2024.[full citation needed]
  7. ^ Iepsen, E. W.; Torekov, S. S.; Holst, J. J. (2015). "Liraglutide for Type 2 diabetes and obesity: a 2015 update". Expert Review of Cardiovascular Therapy. 13 (7): 753–767. doi:10.1586/14779072.2015.1054810. PMID 26106933.
  8. ^ Lau, Jesper; Bloch, Paw; Schäffer, Lauge; Pettersson, Ingrid; Spetzler, Jane; Kofoed, Jacob; Madsen, Kjeld; Knudsen, Lotte Bjerre; McGuire, James; Steensgaard, Dorte Bjerre; Strauss, Holger Martin; Gram, Dorte X.; Knudsen, Sanne Møller; Nielsen, Flemming Seier; Thygesen, Peter; Reedtz-Runge, Steffen; Kruse, Thomas (2015). "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide". Journal of Medicinal Chemistry. 58 (18): 7370–7380. doi:10.1021/acs.jmedchem.5b00726.
  9. ^ "Ozempic (semaglutide) Injection".[full citation needed]
  10. ^ "FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014". Food and Drug Administration.[full citation needed]
  11. ^ Monecke, Angela (13 September 2023). "Für ihre Forschung zu Liraglutid und Semaglutid erhält Dr. Lotte Bjerre Knudsen beim Diabetes Kongress die höchste Auszeichnung der DDG". Medical Tribune. Retrieved 8 January 2024.
  12. ^ "Paul-Langerhans-Medaille für die Entwicklung von Liraglutid bei Adipositas und Typ-2-Diabetes". journalmed.de (in German). 26 May 2023. Retrieved 29 May 2023.
  13. ^ Chen, Elaine (18 October 2023). "Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award". STAT. Retrieved 21 April 2024.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lotte_Bjerre_Knudsen&oldid=1223682658"